awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q26744339-6678C5A1-5785-44F3-A0D6-740F901DDE6E
Q26744339-6678C5A1-5785-44F3-A0D6-740F901DDE6E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26744339-6678C5A1-5785-44F3-A0D6-740F901DDE6E
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
P2860
Q26744339-6678C5A1-5785-44F3-A0D6-740F901DDE6E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26744339-6678C5A1-5785-44F3-A0D6-740F901DDE6E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
45d0296c81393f61613379b9c9b855f2bd8df1f1
P2860
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.